- Tracer Biotechnologies partners with QIAGEN to enhance cancer detection.
- Analysts project a potential 9.10% upside for QIAGEN NV (QGEN, Financial).
- QIAGEN receives an "Outperform" rating from major brokerage firms.
Tracer Biotechnologies has announced a strategic partnership with QIAGEN (QGEN), aiming to advance the development and commercialization of minimal residual disease (MRD) assays for solid tumors. By leveraging QIAGEN's innovative QIAcuity digital PCR platform, this collaboration seeks to provide highly sensitive, cost-effective MRD testing. Such advancements are set to empower oncologists in monitoring cancer recurrence more efficiently through blood sample analysis.
Wall Street Analysts Forecast
According to projections by 14 financial analysts, the average target price for Qiagen NV (QGEN, Financial) is pegged at $49.71. Estimates vary, with a high of $55.00 and a low of $45.00. This suggests a promising 9.10% upside from the current trading price of $45.56. For further detailed insights, consider visiting the Qiagen NV (QGEN) Forecast page.
In terms of market sentiment, 17 brokerage firms provide an average recommendation rating of 2.3 for Qiagen NV (QGEN, Financial), conveying an "Outperform" status. This rating scale ranges from 1 to 5, where 1 indicates a Strong Buy and 5 represents a Sell.
GuruFocus estimates place the GF Value for Qiagen NV (QGEN, Financial) at $48.96 over one year. This evaluation translates to an anticipated 7.46% upside from the current market price of $45.56. The GF Value reflects GuruFocus' assessment of the stock's fair trading value, derived from historical trading multiples, previous business growth, and prospective performance projections. Additional data is accessible on the Qiagen NV (QGEN) Summary page.
